BBIO vs BCTXZ

BridgeBio Pharma, Inc. vs BriaCell Therapeutics Corp. War — Valuation Comparison 2026

BBIO

Pharmaceutical Preparations
BridgeBio Pharma, Inc.
Quality
6.5
out of 10
Value Trap
18
SAFE
Price
$66.26
Last close
Models
8/13
Active
VS

BCTXZ

Pharmaceutical Preparations
BriaCell Therapeutics Corp. War
Quality
4.4
out of 10
Value Trap
24
SAFE
Price
$0.08
Last close
Models
1/13
Active

Model-by-Model Comparison

ModelType BBIO Fair ValueBBIO Upside BCTXZ Fair ValueBCTXZ Upside
Bayesian DCF Intrinsic $19.97 -69.9%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $25.20 -62.8% $0.31 +227.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $63.52 -13.3%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BBIO vs BCTXZ — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BBIO vs BCTXZ — Which Stock Is More Undervalued?

BBIO scores higher with a 6.5/10 quality rating vs BCTXZ's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing BridgeBio Pharma, Inc. (BBIO) and BriaCell Therapeutics Corp. War (BCTXZ) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BBIO currently trades at $66.26 with a QOC of 6.5/10, while BCTXZ trades at $0.08 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).